Outcome of<i>in vitro</i>fertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial

Hong, Ye; Huang, Gangliang; Li, Pei; Zeng, P.; Luo, Xiu

doi:10.3109/09513590.2011.650742

Cited by 21 publications

(18 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the reports included in the review, only one relatively small study (n = 127) provided live-birth data on patients who had not undergone IVF/ICSI prior to randomization,28 in women undergoing an IVF GnRH-agonist cycle. Therefore, we used data from a prospective cohort study conducted in Norway (n = 1,136)29 as the source for the base-case economic evaluation.…”

Section: Methodsmentioning

confidence: 99%

Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden

Wex¹,

Abou‐Setta²

2013

CEOR

View full text Add to dashboard Cite

Gonadotropin-releasing hormone-analog type, fertilization method, and number of embryos available for cryopreservation should be incorporated into economic evaluations of highly purified human menopausal gonadotropin (HP-hMG) and recombinant human follicle-stimulating hormone (r-hFSH), as they may affect treatment costs. We searched for randomized trials and meta-analyses comparing HP-hMG and r-hFSH. Meta-analysis showed no significant difference in live births (odds ratio 0.82, 95% confidence interval [CI] 0.66–1.01), but a greater number of oocytes with r-hFSH (mean difference [MD] 1.96, 95% CI 1.02–2.90). Using a cost-minimization model for Sweden, accounting for embryo availability, survival following thawing, and patient dropout, we simulated patients individually for up to three cycles. R-hFSH was found to be cost-saving, at 2,767 kr (95% CI 1,580–4,057) per patient (€315 or $411); baseline savings were 6.43% of the total HP-hMG cost. In fresh cycles only, the savings for r-hFSH were 1,752 kr (95% CI 48–3,658) per patient (€200 or $260). In univariate sensitivity analyses, savings were obtained until the price of r-hFSH increased by 30% or the dosage of HP-hMG decreased by 38%–62% of baseline value. In probabilistic sensitivity analysis, r-hFSH was cost-saving in 100% of the simulated cohort per patient and in 85% per live birth; the respective percentages for fresh cycles only were 97.3% and 73.1%. In conclusion, a greater number of oocytes with r-hFSH allows for more frozen embryo transfers, thereby reducing overall treatment cost.

show abstract

Section: Methodsmentioning

confidence: 99%

Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden

Wex¹,

Abou‐Setta²

2013

CEOR

View full text Add to dashboard Cite

show abstract

“…Of note, elevated progesterone had no impact on the oocyte and embryo quality thus suggesting that its likely detrimental effect relates to the endometrial receptivity [172]. This hypothesis has been corroborated by data from oocyte donation programs, which indicates that pregnancy rates of the recipients are not influenced by progesterone levels of the donors measured at the day of hCG administration [166,173,174].…”

Section: Clinical Impact Of Progesterone Rise During Cos With Gonadotmentioning

confidence: 74%

“…In the event of COS, multiple follicular growth is achieved. Recombinant FSH has higher FSH bioactivity compared to urinary FSH and hMG, thus leading to the development of more follicles and granulosa cells [97,125,126,[166][167][168]. Furthermore, FSH induces up-regulation of LH receptors in granulosa cells, unlike hMG [22,96].…”

Section: Clinical Impact Of Progesterone Rise During Cos With Gonadotmentioning

confidence: 99%

Gonadotropin in Assisted Reproduction: An Evolution Perspective

Leão¹,

Esteves²

2015

Unexplained Infertility

View full text Add to dashboard Cite

“…On the other hand, studies investigating the effects of folliclestimulating hormone (FSH) + human chorionic gonadotropin (HCG)-driven LH activity combination in HP-HMG and r-hFSHonly mostly involved general infertile women undergoing IVF using either agonist or antagonist protocol (Andersen et al, 2006;Esteves et al, 2009;Kilani et al, 2003;Lehert et al, 2010;Platteau et al, 2008;Shavit et al, 2016). To our knowledge, there are still a few studies that have investigated the effect of FSH + HCG-driven LH activity combination in HP-HMG in poor responders (Ji et al, 2020) or in advanced maternal age (≥35 years old) (Ye et al, 2012). Additionally, previous studies on the effect of LH activity supplementation on POR patients in IVF were mostly conducted in European region on the Caucasian population.…”

Section: Introductionmentioning

confidence: 99%

Comparison of Highly Purified HMG versus Recombinant FSH with Antagonist Protocol in Poor Responder Patients

Polim

Handayani²,

Pratiwi³

et al. 2020

FandR

View full text Add to dashboard Cite

Background:Luteinizing hormone (LH) supplementation may have beneficial effect on the maturity and fertilizability of oocytes in poor ovarian reserve (POR) and may influence the progesterone level, thus increasing the pregnancy rate. However, previous studies on the effect of LH activity supplementation on poor responders have shown conflicting results. This study aimed to compare the clinical effectiveness of two different forms of gonadotropin (highly purified human menopausal gonadotropin (HP-HMG) vs. recombinant human follicle-stimulating hormone (r-hFSH)-only) in Indonesian population. Methods: Women diagnosed with poor ovarian response who received gonadotropin-releasing hormone (GnRH) antagonist protocol with either HP-HMG or r-hFSH-only were investigated. Women who underwent freeze all cycles, mini stimulation, and natural stimulation were excluded. Multiple logistic regression was performed to assess the effect of follicle-stimulating hormone (FSH) + human chorionic gonadotropin (HCG)-driven LH activity combination in HP-HMG to pregnancy event adjusting for progesterone level, demographic variables, and clinical characteristic variables. Results: A total of 101 subjects in the HP-HMG treatment group and 89 subjects in r-hFSH-only treatment group were involved in the study. There was no significant difference of clinical pregnancy rate between HP-HMG group and r-hFSH-only group (adjusted OR: 0.94, 95% CI: 0.39–2.25; p-value: 0.890). Conclusion: Compared to r-hFSH-only group, combination of FSH + HCG-driven LH activity in HP-HMG group had similar effectiveness in poor responders undergoing in vitro fertilization (IVF) using the antagonist protocol.

show abstract

Outcome ofin vitrofertilization following stimulation with highly purified hMG or recombinant FSH in downregulated women of advanced reproductive age: a prospective, randomized and controlled trial

Cited by 21 publications

References 20 publications

Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden

Economic evaluation of highly purified human menopausal gonadotropin versus recombinant human follicle-stimulating hormone in fresh and frozen in vitro fertilization/intracytoplasmic sperm-injection cycles in Sweden

Gonadotropin in Assisted Reproduction: An Evolution Perspective

Comparison of Highly Purified HMG versus Recombinant FSH with Antagonist Protocol in Poor Responder Patients

Contact Info

Product

Resources

About